About this Medicine article

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease by Marc S. Sabatine; Robert P. Giugliano; Anthony C. Keech; Narimon Honarpour; Stephen D. Wiviott; Sabina A. Murphy; Julia F. Kuder; Huei Wang; Thomas Liu; Scott M. Wasserman; Peter S. Sever; Terje R. Pedersen is a Medicine article available to read on EtoBox.

## BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisinkexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. ## Methods We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. ## Results At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter

Author

Marc S. Sabatine; Robert P. Giugliano; Anthony C. Keech; Narimon Honarpour; Stephen D. Wiviott; Sabina A. Murphy; Julia F. Kuder; Huei Wang; Thomas Liu; Scott M. Wasserman; Peter S. Sever; Terje R. Pedersen

Publisher

Massachusetts Medical Society

Published

2017

Language

EN

Field

Medicine (Health Sciences)